Kite Pharma and Cell Design Inc collaborate on CAR-T immunotherapy research
Friday, June 03, 2016
Kite Pharma Inc Will pay cell design labs an upfront payment and additional payments to support cell design labs' research. Arie belldegrun to join board of cell design labs, david chang, evp, research and development, chief medical officer of kite, will join as board observer.
Co, cell design labs, inc announced a research collaboration and license agreement.
To license cell design's synthetic biology technology for applications in acute myeloid leukemia with option for applications in b-cell malignancies.
Increased its equity investment in cell design labs as part of cell design labs' recent private financings.
Source : reuters.com
